North China Pharmaceutical Company.Ltd (SHA:600812)
China
· Delayed Price · Currency is CNY 5.27
+0.02 (0.38%)
Apr 29, 2026, 3:00 PM CST
SHA:600812 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 8,821 | 9,242 | 9,798 | 10,070 | 10,449 | 10,304 | Upgrade
|
| Other Revenue | - | - | 71.76 | 50.32 | 51.19 | 80.2 | Upgrade
|
| Revenue | 8,821 | 9,242 | 9,870 | 10,120 | 10,500 | 10,385 | Upgrade
|
| Revenue Growth (YoY) | -10.78% | -6.36% | -2.48% | -3.62% | 1.11% | -9.64% | Upgrade
|
| Cost of Revenue | 6,090 | 6,376 | 6,732 | 6,907 | 7,063 | 6,691 | Upgrade
|
| Gross Profit | 2,731 | 2,865 | 3,138 | 3,213 | 3,437 | 3,694 | Upgrade
|
| Selling, General & Admin | 1,683 | 1,785 | 2,010 | 2,268 | 2,424 | 2,796 | Upgrade
|
| Research & Development | 355.66 | 341 | 336.15 | 294.2 | 215.17 | 151.93 | Upgrade
|
| Other Operating Expenses | 74.86 | 73.6 | 90.82 | 104.23 | 117.57 | 123.33 | Upgrade
|
| Operating Expenses | 2,158 | 2,244 | 2,465 | 2,677 | 2,802 | 3,094 | Upgrade
|
| Operating Income | 572.66 | 621.36 | 672.93 | 536.44 | 634.8 | 600.11 | Upgrade
|
| Interest Expense | -361.55 | -361.55 | -458.7 | -501.9 | -599.39 | -642.69 | Upgrade
|
| Interest & Investment Income | 78.84 | 86.44 | 71.42 | 74.52 | 84.17 | 126.62 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 17.57 | 11.49 | 23.31 | -8.32 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.75 | -6.9 | -5.15 | -11.35 | -748.96 | -13.91 | Upgrade
|
| EBT Excluding Unusual Items | 309.35 | 339.35 | 298.08 | 109.2 | -606.07 | 61.82 | Upgrade
|
| Impairment of Goodwill | - | - | -3.34 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.84 | 0.83 | 0.31 | 0.76 | 0.21 | 3.4 | Upgrade
|
| Asset Writedown | 10.35 | 17.23 | -1.26 | -0.05 | - | - | Upgrade
|
| Legal Settlements | - | - | -0.5 | -0.49 | -0.78 | -1.14 | Upgrade
|
| Other Unusual Items | - | - | 16.55 | 49.12 | 41.56 | 70.84 | Upgrade
|
| Pretax Income | 320.54 | 357.41 | 309.83 | 158.54 | -565.07 | 134.91 | Upgrade
|
| Income Tax Expense | 90.33 | 99.96 | 94.87 | 109.15 | 113.71 | 99.52 | Upgrade
|
| Earnings From Continuing Operations | 230.2 | 257.45 | 214.97 | 49.39 | -678.78 | 35.38 | Upgrade
|
| Minority Interest in Earnings | -69.17 | -74.4 | -87.97 | -44.5 | -10.45 | -16.65 | Upgrade
|
| Net Income | 161.04 | 183.06 | 126.99 | 4.89 | -689.23 | 18.73 | Upgrade
|
| Net Income to Common | 161.04 | 183.06 | 126.99 | 4.89 | -689.23 | 18.73 | Upgrade
|
| Net Income Growth | -3.18% | 44.15% | 2496.79% | - | - | -80.76% | Upgrade
|
| Shares Outstanding (Basic) | 1,710 | 1,711 | 1,716 | 1,630 | 1,715 | 1,702 | Upgrade
|
| Shares Outstanding (Diluted) | 1,710 | 1,711 | 1,716 | 1,630 | 1,715 | 1,702 | Upgrade
|
| Shares Change (YoY) | -0.92% | -0.31% | 5.27% | -4.92% | 0.70% | 4.96% | Upgrade
|
| EPS (Basic) | 0.09 | 0.11 | 0.07 | 0.00 | -0.40 | 0.01 | Upgrade
|
| EPS (Diluted) | 0.09 | 0.11 | 0.07 | 0.00 | -0.40 | 0.01 | Upgrade
|
| EPS Growth | -2.28% | 44.59% | 2366.67% | - | - | -81.67% | Upgrade
|
| Free Cash Flow | 627.68 | 634.53 | 445.35 | 401.23 | 454.81 | 502.75 | Upgrade
|
| Free Cash Flow Per Share | 0.37 | 0.37 | 0.26 | 0.25 | 0.27 | 0.29 | Upgrade
|
| Dividend Per Share | - | - | 0.030 | 0.010 | - | 0.060 | Upgrade
|
| Dividend Growth | - | - | 200.00% | - | - | 100.00% | Upgrade
|
| Gross Margin | 30.96% | 31.00% | 31.79% | 31.75% | 32.73% | 35.57% | Upgrade
|
| Operating Margin | 6.49% | 6.72% | 6.82% | 5.30% | 6.05% | 5.78% | Upgrade
|
| Profit Margin | 1.83% | 1.98% | 1.29% | 0.05% | -6.56% | 0.18% | Upgrade
|
| Free Cash Flow Margin | 7.12% | 6.87% | 4.51% | 3.96% | 4.33% | 4.84% | Upgrade
|
| EBITDA | 1,493 | 1,516 | 1,461 | 1,275 | 1,347 | 1,224 | Upgrade
|
| EBITDA Margin | 16.93% | 16.40% | 14.81% | 12.60% | 12.83% | 11.79% | Upgrade
|
| D&A For EBITDA | 920.79 | 894.34 | 788.52 | 739.01 | 712 | 624 | Upgrade
|
| EBIT | 572.66 | 621.36 | 672.93 | 536.44 | 634.8 | 600.11 | Upgrade
|
| EBIT Margin | 6.49% | 6.72% | 6.82% | 5.30% | 6.05% | 5.78% | Upgrade
|
| Effective Tax Rate | 28.18% | 27.97% | 30.62% | 68.85% | - | 73.77% | Upgrade
|
| Revenue as Reported | 9,242 | 9,242 | 9,870 | 10,120 | 10,500 | 10,385 | Upgrade
|
| Advertising Expenses | - | - | 119.86 | 133.01 | 127.89 | 185.19 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.